European shares of AstraZeneca fell 9% after its late-stage clinical trial of Wainua, a drug for treating nervous system disorders, failed to meet expectations.
2026-07-09
European shares of AstraZeneca fell 9% after its late-stage clinical trial of Wainua, a drug for treating nervous system disorders, failed to meet expectations.